 Clinical neurophysiological studies aldose reductase inhibitor ponalrestat chronic symptomatic diabetic peripheral neuropathy flux polyol enzyme aldose reductase development diabetic neuropathy Fifty-four diabetic patients median age yr yr chronic neuropathic symptoms reductase inhibition mg ponalrestat ICI groups wk Patients vibration perception thresholds VPTs great toe thermal difference thresholds TTs degrees dorsum foot trial significant changes symptoms pain numbness paresthesia ponalrestat placebo groups improvements VPT TT several sites Posterior tibial nerve conduction velocity m/s baseline m/s wk NS placebo m/s NS mg ponalrestat m/s NS mg ponalrestat Further studies intervention stage evolution neuropathy periods